A history of smoking was associated with worse survival outcomes in male patients with pulmonary arterial hypertension (PAH), according to a new study. The analysis found, however, that smoking history did not significantly affect survival in female PAH patients or in people with chronic thromboembolic pulmonary hypertension (CTEPH).
The proportion of people in the U.S. with pulmonary arterial hypertension related to the use of methamphetamine (Meth-PAH) increased by 93% between 2018 and 2022, a steeper increase than the one seen for the number of U.S. adults self-reporting methamphetamine use, a new study shows. The analysis found that Meth-PAH patients…
Discussion
I’m a ’90s baby, which means medical dramas were at peak popularity during my childhood. Shows like “ER” and “Grey’s Anatomy” were among the big hits, often portraying a fantasy version of healthcare and hospital life. Throughout high school and college, I frequently indulged in this genre. I remember nights…
Winrevair (sotatercept-csrk), an injection therapy approved for adults with pulmonary arterial hypertension (PAH), is now covered by several of Canada’s publicly funded health programs. The therapy’s developer Merck, known as MSD outside the U.S. and Canada, announced that Winrevair has been added to the public drug formularies…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
